The University of Maryland School of Medicine Center for Vaccine Development and global Health is conducting an mRNA vaccine trial to understand the most effective dose for preventing cytomegalovirus (CMV) in children ages 9 to 15. The vaccine has already been looked at for safety in people ages 16 and older.
What Is CMV?
CMV is a common and often overlooked virus with lifelong impact. For most people, the symptoms of CMV—if any—may resemble the common cold with fatigue, headache, and sore throat. Unfortunately, once CMV is in the body it’s there for life, “sleeping” in the body. At certain times in a person’s life, such as pregnancy, CMV can reactivate. Currently, there is no approved vaccine for the prevention of CMV infection.
An active CMV infection during pregnancy puts the unborn baby at risk of birth defects. These include hearing loss, vision loss, or cerebral palsy, which can lead to long-term disability or, in severe cases, death.
Participants can receive compensation up to $2,560. Your involvement advances CMV research.
What to Expect in the CMVibe Trial
The total length of participation in this clinical trial is approximately 1½ years (18 months).
The participants and researchers will both know which dose the participant is getting. Every clinical trial participant will get the same level of care regardless of which dose level they receive.
Clinical Trial Participants Are Essential
Vaccines aim to protect people against viral infections, and clinical trials are an important step in creating vaccines. Without clinical trial participants, researching potential new vaccines would not be possible.
Ready to get started?
Call: 410-706-8800 (8am-4pm)
Or complete our contact form.